Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 466-468

  Khanna, Dinesh ^a,b   Clements, Philip J ^a   Postlethwaite, Arnold E ^c   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Clinical trial; Health assessment questionnaire disability index; Systemic sclerosis

Indexed keywords

COLLAGEN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SCORING SYSTEM; SYSTEMIC SCLEROSIS;

ACTIVITIES OF DAILY LIVING; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DISABILITY EVALUATION; HUMANS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCLERODERMA, DIFFUSE; SELF-HELP DEVICES; SEVERITY OF ILLNESS INDEX;

EID: 40649119028     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
2. Furst D, Khanna D, Matucci-Cerinic M, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194-200.
3. Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
4. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7.
5. Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
6. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
7. Cole JC, Khanna D, Clements PJ, et al. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006;15:1383-94.
8. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
9. Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
10. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta-1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2006;56:323-33.
11. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
12. Postlethwaite A, Furst D, Wong WK, Clements P. Oral tolerance (OT) induction to type I collagen (CI) significantly reduces the skin score in patients with diffuse systemic sclerosis (SSc) with late-phase disease. Results of a NIAMS/NIAID multicenter phase II placebo-controlled double blind clinical trial [abstract]. Arthritis Rheum 2005.
13. Khanna D, Furst DE, Wong WK, et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007;16:1083-92.
14. The Health Assessment Questionnaire. [Internet. Accessed November 21, 2007.] Available from: http://www.chcr.brown.edu/pcoc/EHAQDESCRSCORINGHAQ372.pdf
15. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953-60.
16. Krishnan E, Tugwell P, Fries JF. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). Arthritis Res Ther 2004;6:R505-R513.
17. Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. Arthritis Rheum 2007;56:1676-84.
18. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis - results from the D-Penicillamine Study. Ann Rheum Dis 2006;65:1325-9.
19. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology Oxford 2004;43:640-7.